Abstract
Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.
| Original language | English |
|---|---|
| Pages (from-to) | 2357-2367 |
| Number of pages | 11 |
| Journal | International Journal of Cancer |
| Volume | 138 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - May 15 2016 |
Fingerprint
Keywords
- lymphoma
- meta-analyses
- prospective study
- sCD27
- sCD30
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas : A nested case-control study and meta-analyses. / Hosnijeh, Fatemeh Saberi; Portengen, Lutzen; Späth, Florentin; Bergdahl, Ingvar A.; Melin, Beatrice; Mattiello, Amalia; Masala, Giovanna; Sacerdote, Carlotta; Naccarati, Alessio; Krogh, Vittorio; Tumino, Rosario; Chadeau-Hyam, Marc; Vineis, Paolo; Vermeulen, Roel.
In: International Journal of Cancer, Vol. 138, No. 10, 15.05.2016, p. 2357-2367.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas
T2 - A nested case-control study and meta-analyses
AU - Hosnijeh, Fatemeh Saberi
AU - Portengen, Lutzen
AU - Späth, Florentin
AU - Bergdahl, Ingvar A.
AU - Melin, Beatrice
AU - Mattiello, Amalia
AU - Masala, Giovanna
AU - Sacerdote, Carlotta
AU - Naccarati, Alessio
AU - Krogh, Vittorio
AU - Tumino, Rosario
AU - Chadeau-Hyam, Marc
AU - Vineis, Paolo
AU - Vermeulen, Roel
PY - 2016/5/15
Y1 - 2016/5/15
N2 - Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.
AB - Prediagnostic serum/plasma concentrations of B-cell activation markers have been associated with future risk of B-cell lymphomas (BCL) in HIV-infected patients and in the general population. Current evidence for the general population is however limited and relies on relatively small numbers of observations, especially for specific histologies. We carried out a nested case-control study, including 218 BCL and 218 matched controls, within two prospective cohorts, to investigate the association between plasma levels of soluble (s)CD27 and sCD30 and future risk of BCL, and main histologic subtypes separately. To expand the evidence further, we performed meta-analyses of the published data on these associations from prospective studies among the general population. Our study revealed a significant relationship between sCD30 concentration and BCL risk (OR = 0.86, 1.53, 1.76, for the 2nd-4th quartiles respectively, p trend = 0.01). Similar increased risks were observed for diffuse large B-cell lymphoma and follicular lymphoma. Analyses of sCD27 blood concentrations did not show significant associations with BCL, (OR = 0.90, 1.26, 1.65 for the 2nd-4th quartiles, respectively, p trend = 0.17), but significant associations were observed for chronic lymphocytic leukaemia and for the group of "other BCL" subtypes. Our findings involving sCD30 were confirmed within our meta-analyses of five prospective cohorts, while results were more heterogeneous for sCD27 with the exception of CLL which was found consistently in all studies. Data to date suggest that chronic B-cell stimulation might be an important mechanism involved in B-cell lymphomagenesis both in HIV-infected and in the general population.
KW - lymphoma
KW - meta-analyses
KW - prospective study
KW - sCD27
KW - sCD30
UR - http://www.scopus.com/inward/record.url?scp=84959879060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959879060&partnerID=8YFLogxK
U2 - 10.1002/ijc.29969
DO - 10.1002/ijc.29969
M3 - Article
C2 - 26684261
AN - SCOPUS:84959879060
VL - 138
SP - 2357
EP - 2367
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 10
ER -